Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced on January 9, 2017 that it is actively involved in five programs and projects that are funded by leading biotech and pharmaceutical companies to develop and validate multi-marker liquid biopsy tests for a broad range of solid tumors. CGI expects that revenue from these projects will begin immediately and will help the Company accelerate the development of multi-marker companion and complementary liquid biopsy diagnostics. These five programs range across a variety of cancers including: breast, lung, renal, prostate, and gastro-intestinal. Healthcare analysts at J.P. Morgan predict that the liquid biopsy market could be worth as much as $20 billion by 2020, and replace traditional tissue-based biopsies in a wide range of cancers. Analysts also expect that liquid biopsies may open the market to new, cost-effective ways to routinely assess the effectiveness of cancer therapies and detect cancers earlier and with higher sensitivity. “There are a wide range of platforms and methods being used in liquid biopsy today, and CGI is uniquely positioned to rapidly create high-performance, clinically useful liquid biopsy tests for our biotech and pharmaceutical partners,” commented Mr. Panna Sharma, CEO & President of Cancer Genetics.
Login Or Register To Read Full Story